Mannitozaf

Mannitozaf Uses, Dosage, Side Effects, Food Interaction and all others data.

Mannitozaf increases urinary output by inhibiting tubular reabsorption of water and electrolytes. It raises the osmotic pressure of the plasma allowing water to be drawn out of body tissues.

Chemically, mannitol is an alcohol and a sugar, or a polyol; it is similar to xylitol or sorbitol. However, mannitol has a tendency to lose a hydrogen ion in aqueous solutions, which causes the solution to become acidic. For this reason, it is not uncommon to add a substance to adjust its pH, such as sodium bicarbonate. Mannitozaf is commonly used to increase urine production (diuretic). It is also used to treat or prevent medical conditions that are caused by an increase in body fluids/water (e.g., cerebral edema, glaucoma, kidney failure). Mannitozaf is frequently given along with other diuretics (e.g., furosemide, chlorothiazide) and/or IV fluid replacement.

Inhaled mannitol has the possibility to cause bronchospasm and hemoptysis; the occurrence of either should lead to discontinuation of inhaled mannitol.

Trade Name Mannitozaf
Availability Prescription only
Generic Mannitol
Mannitol Other Names D-Mannitol, Manitol, Manna Sugar, Mannit, Mannite, Mannitol, Mannitolum
Related Drugs furosemide, azithromycin, dexamethasone, Lasix, gentamicin, Zithromax, Decadron, Creon, tobramycin, glucagon
Weight 20%
Type Infusion
Formula C6H14O6
Weight Average: 182.1718
Monoisotopic: 182.07903818
Groups Approved, Investigational
Therapeutic Class Osmotic diuretics
Manufacturer Zafa Pharmaceutical Laboratories (pvt) Ltd,
Available Country Pakistan
Last Updated: September 19, 2023 at 7:00 am
Mannitozaf
Mannitozaf

Uses

Mannitozaf is principally used by IV infusion as an osmotic diuretic to preserve renal function in acute renal failure and to reduce raised intracranial and intraocular pressure. Mannitozaf is also used as an irrigating solution to prevent hemolysis and hemoglobin buildup during transurethral prostatic resection. It is useful in the management of acute drug poisoning where a route of elimination is through kidney. Besides these, it is also used in symptomatic relief of edema, reperfusion injury, termination of pregnancy, and bowel preparation. So, Mannitozaf is used for-

Renal insufficiency, Reperfusion injury, Raised intracranial pressure, Bladder irrigation, Raised intraocular presure, Bowel preparation, Edematous status, As a prophylactic in renal failure, Management of poisoning, Termination of Pregnancy

Mannitozaf is also used to associated treatment for these conditions: Acute Renal Failure (ARF), Cystic Fibrosis (CF), Edema of the cerebrum, Increased Intra Ocular Pressure (IOP), Bladder irrigation therapy

How Mannitozaf works

Mannitozaf is an osmotic diuretic that is metabolically inert in humans and occurs naturally, as a sugar or sugar alcohol, in fruits and vegetables. Mannitozaf elevates blood plasma osmolality, resulting in enhanced flow of water from tissues, including the brain and cerebrospinal fluid, into interstitial fluid and plasma. As a result, cerebral edema, elevated intracranial pressure, and cerebrospinal fluid volume and pressure may be reduced. As a diurectic mannitol induces diuresis because it is not reabsorbed in the renal tubule, thereby increasing the osmolality of the glomerular filtrate, facilitating excretion of water, and inhibiting the renal tubular reabsorption of sodium, chloride, and other solutes. Mannitozaf promotes the urinary excretion of toxic materials and protects against nephrotoxicity by preventing the concentration of toxic substances in the tubular fluid. As an Antiglaucoma agent mannitol levates blood plasma osmolarity, resulting in enhanced flow of water from the eye into plasma and a consequent reduction in intraocular pressure. As a renal function diagnostic aid mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. Therefore, its urinary excretion rate may serve as a measurement of glomerular filtration rate (GFR).

The exact mechanism of action of inhaled mannitol in the symptomatic maintenance treatment of cystic fibrosis remains unclear. It is hypothesized that mannitol produces an osmotic gradient across the airway epithelium that draws fluid into the extracellular space and alters the properties of the airway surface mucus layer, allowing easier mucociliary clearance.

Dosage

Mannitozaf dosage

The adult dose of Mannitozaf ranges from 50 to 100 gm by IV infusion. The rate of administration is usually adjusted to maintain a urine flow of at least 30 to 50 ml/hr. Total dosage, concentration and the rate of administration depends on fluid requirement, urinary output and the severity of the condition being treated

Renal insufficiency-

  • Adults: 50 to 100 g of Mannitozaf administered at a rate adjusted to maintain a urine flow of at least 30 to 50 ml/hr.
  • Children: 2 gm/kg or 60 gm/m2of body surface area administered over a period of 2 to 6 hrs.

Cerebral edema, elevated intracranial pressure, elevated intraocular pressure, Glaucoma-

  • Adults: 1.5 to 2 gm/kgadministered over a period of 30 to 60 minutes.
  • Children: 1 to 2 gm/kg body wt. or 30 to 60 gm/m2 of body surface area administered over a period of 30 to 60 mins.

Adjunctive therapy for removal of toxic substances-

  • Adults: 50 to 200 g of Mannitozaf administered at a rate adjust to maintain a urine flow of at least 100 to 500 ml/hr.
  • Children: 2 gm/kg or 60 gm/m2of body surface area

For termination of pregnancy 50 gm of Mannitozaf (250 ml of Mannitozaf) is instilled into the amniotic cavity which induces abortion in a high proportion of pregnancies.

Side Effects

The most common side effects associated with Mannitozaf intravenous infusion is fluid and electrolytes imbalance including circulatory overload and acidosis at high doses. Other side effects include nausea, vomiting, thirst, headache, dizziness, fever, tachycardia, chest pain, hyponatraemia, dehydration, blurred vision, urticaria, and hypertension or hypotension.

Toxicity

Mannitozaf overdose may result in bronchoconstriction and should be counteracted using a short-acting bronchodilator and other symptomatic and supportive care, as necessary.

Precaution

Careful monitoring of rate of administration of Mannitozaf is necessary to avoid fluid and electrolyte imbalance and circulatory overloading. The infusion should be discontinued if the patient develops signs of progressive renal dysfunction, heart failure or pulmonary congestion. Mannitozaf should not be administered with whole blood.

Interaction

Increased nephrotoxicity with ciclosporin.

Food Interaction

No interactions found.

Volume of Distribution

Mannitozaf administered intravenously has a volume of distribution of 34.3 L.

Elimination Route

Approximately 7% of ingested mannitol is absorbed during gastrointestinal perfusion in uremic patients.

Inhalation of 635 mg of mannitol powder yields a plasma Cmax of 13.71 μg/mL in 1.5 hours (Tmax) and a mean systemic AUC of 73.15 μg*h/mL.

Half Life

Mannitozaf has an elimination half-life of 4.7 hours following oral administration; the mean terminal elimination half-life is similar regardless of administration route (oral, inhalation, and intravenous.

Clearance

Intravenous administration of mannitol yields a total clearance of 5.1 L/hr and renal clearance of 4.4 L/hr.

Elimination Route

Mannitozaf is primarily excreted unchanged in the urine. Following oral inhalation of 635 mg of mannitol in healthy volunteers, 55% of the total dose was recovered unchanged in the urine; following oral or intravenous administration of 500 mg, the corresponding values were 54 and 87%, respectively.

Pregnancy & Breastfeeding use

Safety of Mannitozaf intravenous infusion in pregnancy has not been established yet. No information is available on the excretion of mannitol in breast milk and should be administered after careful consideration of risk-benefit ratio.

Contraindication

Mannitozaf intravenous infusion is contraindicated in patients with pulmonary edema or congestive heart failure. It is also contraindicated during inadequate urine flow, dehydration or acidosis, intracranial bleeding and in patients with renal failure unless a test dose has produced a diuretic response

Storage Condition

Mannitozaf should be stored at a temperature of 20° to 30°. Exposure to lower temperatures may cause deposition of crystals, which should be dissolved by warming the bottle in hot water for about 30 minutes. Cool to body temperature before using. If all crystals can not be dissolved, the solution should not be used. The content of open containers should be used promptly. Unused contents should be discarded.

Innovators Monograph

You find simplified version here Mannitozaf

Mannitozaf contains Mannitol see full prescribing information from innovator Mannitozaf Monograph, Mannitozaf MSDS, Mannitozaf FDA label

http://classyfire.wishartlab.com/tax_nodes/C0000000
http://classyfire.wishartlab.com/tax_nodes/C0004603
http://classyfire.wishartlab.com/tax_nodes/C0000323
http://classyfire.wishartlab.com/tax_nodes/C0000011
http://classyfire.wishartlab.com/tax_nodes/C0002210
http://classyfire.wishartlab.com/tax_nodes/C0001540
http://classyfire.wishartlab.com/tax_nodes/C0001661
http://classyfire.wishartlab.com/tax_nodes/C0002286
http://classyfire.wishartlab.com/tax_nodes/C0000286
http://classyfire.wishartlab.com/tax_nodes/C0004150
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:16899
http://www.hmdb.ca/metabolites/HMDB0000765
http://www.genome.jp/dbget-bin/www_bget?drug:D00062
http://www.genome.jp/dbget-bin/www_bget?cpd:C00392
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=6251
https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?sid=46506446
https://www.chemspider.com/Chemical-Structure.6015.html
http://www.bindingdb.org/bind/chemsearch/marvin/MolStructure.jsp?monomerid=50142798
https://mor.nlm.nih.gov/RxNav/search?searchBy=RXCUI&searchTerm=6628
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=16899
https://www.ebi.ac.uk/chembldb/index.php/compound/inspect/CHEMBL689
https://zinc.docking.org/substances/ZINC000002041302
http://bidd.nus.edu.sg/group/cjttd/ZFTTDDRUG.asp?ID=DAP000874
http://www.pharmgkb.org/drug/PA450320
https://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/MTL
http://www.rxlist.com/cgi/generic4/osmitrol.htm
https://www.drugs.com/cdi/mannitol.html
https://en.wikipedia.org/wiki/Mannitol
*** Taking medicines without doctor's advice can cause long-term problems.
Share